ADAPTIVE BIOTECHNOLOGIES CORPORATION

Adaptive Biotechnologies Corporation specializes in high-throughput immune receptor sequencing and diagnostic testing services, leveraging proprietary next-generation sequencing platforms to analyze T-cell and B-cell repertoires for clinical and research applications. Their core capabilities center on the Immunoseq and ClonoSeq platforms, enabling precise detection of minimal residual disease, immune response profiling, and infectious disease monitoring through deep sequencing of T-cell receptor and immunoglobulin genes. The company delivers FDA-cleared in vitro diagnostic services with clinical-grade accuracy, supporting precision oncology, immunotherapy monitoring, and infectious disease research. Technical expertise includes bioinformatics analysis of adaptive immune repertoires, assay validation for clinical laboratories, and regulatory-compliant reporting for diagnostic use. The contractor maintains strong, recurring relationships with the Department of Health and Human Services, the Department of Veterans Affairs, and the Department of Defense. For HHS, they provide immunosequencing services for infectious disease surveillance and immune monitoring programs. The VA relies on their ClonoSeq platform for longitudinal tracking of blood cancers across multiple Veterans Health Administration networks. The DoD engages them for immune profiling in military health research and diagnostic testing applications, particularly in hematologic malignancies. Their primary industry focus is in clinical and research laboratories serving life sciences, with deep specialization in immunosequencing as a diagnostic and research tool under NAICS 541380 and 541714. They position themselves as a technical leader in immune repertoire analysis, bridging translational research with validated clinical diagnostics. Adaptive Biotechnologies Corporation is a small business headquartered in Seattle, Washington, with no government certifications on record. Their operational presence is centered in the Pacific Northwest, serving federal agencies through advanced biotechnology services with a focus on clinical implementation of genomic insights.